Epigral Resultados de beneficios anteriores
Pasado controles de criterios 2/6
Epigral ha aumentado sus beneficios a una tasa media anual de 10.8%, mientras que los beneficios de la industria de Chemicals han experimentado un crecimiento de 7.2% anual. Los ingresos han ido creciendo a una tasa media de 13% al año. La rentabilidad financiera de Epigral es de 16.1%, y sus márgenes netos son de 14%.
Información clave
10.84%
Tasa de crecimiento de los beneficios
10.04%
Tasa de crecimiento del BPA
| Crecimiento de la industria Chemicals | 17.68% |
| Tasa de crecimiento de los ingresos | 12.98% |
| Rentabilidad financiera | 16.08% |
| Margen neto | 13.97% |
| Próxima actualización de resultados | 02 May 2026 |
Actualizaciones de resultados anteriores recientes
Recent updates
EPIGRAL: Steady ₹2,000 View Ahead Of 2026 Postal Ballot Outcome
Epigral's analyst fair value estimate is maintained at ₹2,000, with only marginal tweaks to the discount rate, revenue growth, profit margin and future P/E assumptions, as analysts fine tune their model inputs rather than changing their core view on the stock. What's in the News Epigral has scheduled a Special or Extraordinary Shareholders Meeting on May 19, 2026, to be conducted via postal ballot in India (Key Developments).EPIGRAL: Steady ₹2,000 View Will Await Q3 Board Outcome
Analysts now keep Epigral's fair value estimate broadly unchanged at about ₹2,000 per share, with only minor tweaks to discount rate, revenue growth, profit margin and future P/E assumptions. This signals a largely steady view on the stock's valuation drivers.EPIGRAL: Steady ₹2,000 Outlook Will Anticipate Q3 Board Meeting Outcome
Analysts have kept Epigral's fair value estimate steady at ₹2,000, with only minor tweaks to the discount rate, revenue growth, profit margin assumptions and future P/E supporting an unchanged price target. What's in the News A board meeting is scheduled on January 30, 2026 to consider the unaudited standalone and consolidated financial results for the third quarter and nine months ended December 31, 2025, along with the limited review report.EPIGRAL: Steady ₹2,000 Fair Value Will Anticipate Q3 Board Review Outcome
Analysts have kept Epigral’s fair value estimate steady at ₹2,000, with only small tweaks to assumptions such as discount rate, revenue growth, profit margin and future P/E. This reflects fine tuning of their models rather than a material change in conviction.EPIGRAL: Reaffirmed ₹2,000 Fair Value Will Support Future Repricing
Analysts have maintained Epigral's fair value estimate at ₹2,000. A slightly lower assumed future P/E and a marginally higher discount rate together support this unchanged price target.EPIGRAL: New CFO And Reaffirmed Fair Value Will Support Future Repricing
Analysts now see fair value for Epigral at ₹2,000.00 per share, with the unchanged target based on updated assumptions on discount rate, revenue growth, profit margin and future P/E that together reflect a recalibration of their long term earnings and valuation framework. What's in the News A board meeting is scheduled on January 30, 2026 to consider unaudited standalone and consolidated financial results for the third quarter and nine months ended December 31, 2025, along with the limited review report from statutory auditors (company filing).EPIGRAL: New CFO And Reaffirmed Fair Value Will Support Future Repricing
Analysts have maintained Epigral's fair value estimate at ₹2,000 after updating their assumptions for discount rate, revenue growth, profit margin and future P/E. These revisions support a recalibrated price target narrative rather than a change in the overall valuation direction.EPIGRAL: New CFO Appointment Is Expected To Strengthen Future Financial Governance
Analysts have cut their price target on Epigral from ₹2,600 to ₹2,000, citing updated assumptions that combine slightly higher revenue growth and profit margins with a lower future P/E multiple. What's in the News Epigral appointed Mr. Rakesh Agrawal as Chief Financial Officer and Key Managerial Personnel, effective 10 November 2025, following a board decision based on the Nomination and Remuneration Committee's recommendation (Key Developments).Returns On Capital At Epigral (NSE:EPIGRAL) Have Hit The Brakes
Dec 26
Downgrade: What You Need To Know About The Latest Epigral Limited (NSE:EPIGRAL) Forecasts
Nov 16Epigral Limited Just Missed Earnings - But Analysts Have Updated Their Models
Nov 13If EPS Growth Is Important To You, Epigral (NSE:EPIGRAL) Presents An Opportunity
Nov 11Epigral (NSE:EPIGRAL) Has A Pretty Healthy Balance Sheet
Sep 28Capacity Expansion And Green Energy Will Unlock Global Opportunities
The increase in Epigral’s consensus analyst price target to ₹2600 primarily reflects higher anticipated future earnings multiples, as indicated by the rise in future P/E, while the discount rate remains stable. What's in the News Upcoming board meeting to consider un-audited Q1 FY26 results and review fund-raising proposals via debt instruments.Epigral Limited Just Recorded A 98% EPS Beat: Here's What Analysts Are Forecasting Next
Aug 06Epigral Limited (NSE:EPIGRAL) Might Not Be As Mispriced As It Looks
Jul 30Investors Should Be Encouraged By Epigral's (NSE:EPIGRAL) Returns On Capital
Jun 02Subdued Growth No Barrier To Epigral Limited (NSE:EPIGRAL) With Shares Advancing 25%
Apr 03Calculating The Fair Value Of Epigral Limited (NSE:EPIGRAL)
Feb 28
Doubling CPVC And ECH Production Will Strengthen Future Prospects
Epigral is expanding production capacity and focusing on high-margin value-added products to enhance earnings and future growth.Here's Why Epigral (NSE:EPIGRAL) Has Caught The Eye Of Investors
Dec 18Epigral Limited's (NSE:EPIGRAL) Shares Leap 29% Yet They're Still Not Telling The Full Story
Jul 04Epigral Limited (NSE:EPIGRAL) Looks Just Right With A 27% Price Jump
Apr 19Epigral Limited (NSE:EPIGRAL) Soars 28% But It's A Story Of Risk Vs Reward
Feb 23Epigral (NSE:EPIGRAL) Might Be Having Difficulty Using Its Capital Effectively
Feb 21Capital Investment Trends At Meghmani Finechem (NSE:MFL) Look Strong
Apr 05With EPS Growth And More, Meghmani Finechem (NSE:MFL) Makes An Interesting Case
Sep 28Meghmani Finechem's (NSE:MFL) Promising Earnings May Rest On Soft Foundations
May 03Desglose de ingresos y gastos
Cómo gana y gasta dinero Epigral. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).
Historial de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Gastos G+A | Gastos de I+D |
|---|---|---|---|---|
| 31 Dec 25 | 24,187 | 3,379 | 1,371 | 0 |
| 30 Sep 25 | 24,668 | 4,024 | 1,346 | 0 |
| 30 Jun 25 | 25,055 | 4,325 | 1,301 | 0 |
| 31 Mar 25 | 25,501 | 3,577 | 1,275 | 0 |
| 31 Dec 24 | 24,471 | 3,481 | 1,212 | 0 |
| 30 Sep 24 | 22,734 | 2,935 | 1,146 | 0 |
| 30 Jun 24 | 21,255 | 2,502 | 1,085 | 0 |
| 31 Mar 24 | 19,292 | 1,959 | 1,019 | 0 |
| 31 Dec 23 | 19,667 | 1,953 | 887 | 0 |
| 30 Sep 23 | 20,331 | 2,234 | 871 | 0 |
| 30 Jun 23 | 21,104 | 2,770 | 865 | 0 |
| 31 Mar 23 | 21,884 | 3,533 | 886 | 0 |
| 31 Dec 22 | 21,250 | 3,756 | 924 | 0 |
| 30 Sep 22 | 20,093 | 3,682 | 895 | 0 |
| 30 Jun 22 | 17,934 | 3,236 | 848 | 0 |
| 31 Mar 22 | 15,509 | 2,528 | 768 | 0 |
| 31 Mar 21 | 8,286 | 1,008 | 536 | 0 |
| 31 Mar 20 | 6,098 | 1,141 | 441 | 0 |
| 31 Mar 19 | 7,104 | 1,828 | 482 | 0 |
| 31 Mar 18 | 5,975 | 1,555 | 371 | 0 |
| 31 Mar 17 | 3,921 | 665 | 150 | 0 |
| 31 Mar 16 | 3,982 | 672 | 120 | 0 |
Ingresos de calidad: EPIGRAL tiene ganancias de alta calidad.
Margen de beneficios creciente: Los actuales márgenes de beneficio(14%) de EPIGRAL son inferiores a los del año pasado (14.2%).
Análisis del flujo de caja libre vs. Beneficios
Análisis del crecimiento de los beneficios en el pasado
Tendencia de beneficios: Los beneficios de EPIGRAL han crecido un 10.8% al año en los últimos 5 años.
Acelerando crecimiento: EPIGRAL ha tenido un crecimiento negativo de los beneficios en el último año, por lo que no puede compararse con su media de 5 años.
Beneficios vs. Industria: EPIGRAL tuvo un crecimiento negativo de los beneficios (-2.9%) durante el año pasado, lo que dificulta la comparación con la media de la industria Chemicals (8.7%).
Rentabilidad financiera
Alta ROE: La rentabilidad financiera de EPIGRAL (16.1%) se considera baja.
Rentabilidad económica
Rendimiento del capital invertido
Descubre empresas con buenos resultados en el pasado
Análisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/05/01 08:45 |
| Precio de las acciones al final del día | 2026/04/30 00:00 |
| Beneficios | 2025/12/31 |
| Ingresos anuales | 2025/03/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
Epigral Limited está cubierta por 3 analistas. 1 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| null null | BP Wealth Management Private Limited |
| null null | Emkay Global Financial Services Ltd. |
| Meet Vora | Emkay Global Financial Services Ltd. |